Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Summary Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled...
Internal Medicine | ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | PREDNISONE | DESIGN | MITOXANTRONE | CABAZITAXEL | CLINICAL-TRIALS | OPEN-LABEL | CHEMOTHERAPY | ENZALUTAMIDE | ESTRAMUSTINE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Aged, 80 and over | Adult | Diphosphonates - adverse effects | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Imidazoles - adverse effects | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Diphosphonates - administration & dosage | Zoledronic Acid | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Survival analysis | Medical prognosis | Clinical trials | Hormone replacement therapy | Metastasis | Prostate cancer | Cancer therapies
Internal Medicine | ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | PREDNISONE | DESIGN | MITOXANTRONE | CABAZITAXEL | CLINICAL-TRIALS | OPEN-LABEL | CHEMOTHERAPY | ENZALUTAMIDE | ESTRAMUSTINE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Aged, 80 and over | Adult | Diphosphonates - adverse effects | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Imidazoles - adverse effects | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Diphosphonates - administration & dosage | Zoledronic Acid | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Survival analysis | Medical prognosis | Clinical trials | Hormone replacement therapy | Metastasis | Prostate cancer | Cancer therapies
Journal Article
The Lancet, ISSN 0140-6736, 12/2018, Volume 392, Issue 10162, pp. 2353 - 2366
Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that...
SURVIVAL | MEDICINE, GENERAL & INTERNAL | MEN | RADICAL PROSTATECTOMY | TIME | BONE | ANDROGEN DEPRIVATION THERAPY | RADIATION-THERAPY | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Lymph Nodes - pathology | Prostatic Neoplasms - surgery | Standard of Care | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Gonadotropin-Releasing Hormone - antagonists & inhibitors | Radiotherapy - adverse effects | Orchiectomy | Disease-Free Survival | Neoplasm Metastasis | Survival Analysis | Docetaxel - therapeutic use | Aged | Gonadotropin-Releasing Hormone - agonists | Prostatic Neoplasms - drug therapy | Metastasis | Radiotherapy | Prostate cancer | Analysis | Drug abuse | Substance abuse treatment | Prostate-specific antigen | Radiation | Bladder | Subgroups | Metastases | Randomization | Motivation | Nonsteroidal anti-inflammatory drugs | Urogenital system | Medical research | Aspirin | Deprivation | Hazards | Inflammation | Radiation therapy | Patients | Survival | Androgens | Hypotheses | Medical prognosis | Men | Prostate | Cancer | Tumors
SURVIVAL | MEDICINE, GENERAL & INTERNAL | MEN | RADICAL PROSTATECTOMY | TIME | BONE | ANDROGEN DEPRIVATION THERAPY | RADIATION-THERAPY | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Lymph Nodes - pathology | Prostatic Neoplasms - surgery | Standard of Care | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Gonadotropin-Releasing Hormone - antagonists & inhibitors | Radiotherapy - adverse effects | Orchiectomy | Disease-Free Survival | Neoplasm Metastasis | Survival Analysis | Docetaxel - therapeutic use | Aged | Gonadotropin-Releasing Hormone - agonists | Prostatic Neoplasms - drug therapy | Metastasis | Radiotherapy | Prostate cancer | Analysis | Drug abuse | Substance abuse treatment | Prostate-specific antigen | Radiation | Bladder | Subgroups | Metastases | Randomization | Motivation | Nonsteroidal anti-inflammatory drugs | Urogenital system | Medical research | Aspirin | Deprivation | Hazards | Inflammation | Radiation therapy | Patients | Survival | Androgens | Hypotheses | Medical prognosis | Men | Prostate | Cancer | Tumors
Journal Article
LANCET, ISSN 0140-6736, 10/2019, Volume 394, Issue 10207, pp. 1415 - 1424
Background Remote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been shown to reduce myocardial infarct size in...
LIMB | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | ISCHEMIA/REPERFUSION INJURY | TASK-FORCE | SIZE | ADJUNCT | ST-SEGMENT ELEVATION | CARDIOPROTECTION | Heart failure | Myocardial infarction | Heart | Stroke | Heart attacks | Cardiac conditioning | Mortality | Medical services | Patients | Clinical outcomes | Studies | Side effects | Randomization | Reperfusion | Motivation | Ischemia | Coronary vessels | Electrocardiography | Data collection | Death | Conditioning | Heart diseases | Veins & arteries
LIMB | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | ISCHEMIA/REPERFUSION INJURY | TASK-FORCE | SIZE | ADJUNCT | ST-SEGMENT ELEVATION | CARDIOPROTECTION | Heart failure | Myocardial infarction | Heart | Stroke | Heart attacks | Cardiac conditioning | Mortality | Medical services | Patients | Clinical outcomes | Studies | Side effects | Randomization | Reperfusion | Motivation | Ischemia | Coronary vessels | Electrocardiography | Data collection | Death | Conditioning | Heart diseases | Veins & arteries
Journal Article
European Heart Journal, ISSN 0195-668X, 03/2019, Volume 40, Issue 28, pp. 2290 - 2300
AIMS: Several factors are known to increase risk for cerebrovascular disease and dementia, but there is limited evidence on associations between multiple...
Brain | CARDIAC & CARDIOVASCULAR SYSTEMS | DEMENTIA | WHITE-MATTER INTEGRITY | MRI | ATROPHY | Cortex | COGNITIVE IMPAIRMENT | White matter | DECLINE | PRESSURE | Vascular risk | DISEASE | Diffusion | AGE | LIFE | Editor's Choice | Fast Track Clinical Research
Brain | CARDIAC & CARDIOVASCULAR SYSTEMS | DEMENTIA | WHITE-MATTER INTEGRITY | MRI | ATROPHY | Cortex | COGNITIVE IMPAIRMENT | White matter | DECLINE | PRESSURE | Vascular risk | DISEASE | Diffusion | AGE | LIFE | Editor's Choice | Fast Track Clinical Research
Journal Article
5.
Full Text
Abstracts of the HIV Research for Prevention Meeting, HIVR4P, 21-25 October, 2018, Madrid
AIDS Research and Human Retroviruses, ISSN 0889-2229, 10/2018, Volume 34, Issue S1, pp. 1 - 407
Journal Article
The Lancet Respiratory Medicine, ISSN 2213-2600, 03/2019, Volume 7, Issue 3, pp. 227 - 238
Rare genetic variants cause pulmonary arterial hypertension, but the contribution of common genetic variation to disease risk and natural history is poorly...
SOX17 | ENDODERM FORMATION | RESPIRATORY SYSTEM | SUSCEPTIBILITY | DISEASE | ALPHA | CRITICAL CARE MEDICINE | Life Sciences
SOX17 | ENDODERM FORMATION | RESPIRATORY SYSTEM | SUSCEPTIBILITY | DISEASE | ALPHA | CRITICAL CARE MEDICINE | Life Sciences
Journal Article
Chemistry – A European Journal, ISSN 0947-6539, 02/2015, Volume 21, Issue 7, pp. 2780 - 2784
Herein, we report the synthesis, the thermochemical data, and the catalytic reactivity of a new mononuclear cobalt complex, which has four NH protons in the...
N ligands | cobalt | electron transfer | water splitting | Electron transfer | Water splitting | Cobalt | DEPROTONATION | IMIDAZOLE COMPLEXES | DIOXYGEN | PYRIDINE | COPPER(II) | STATE | CHEMISTRY, MULTIDISCIPLINARY | HYDROGEN | O-2 | COUPLED ELECTRON-TRANSFER | METAL-COMPLEXES | Oxidation-reduction reaction | Ligands | Synthesis | Catalysts | Electrocatalysts | Joining | Oxidation | Catalysis
N ligands | cobalt | electron transfer | water splitting | Electron transfer | Water splitting | Cobalt | DEPROTONATION | IMIDAZOLE COMPLEXES | DIOXYGEN | PYRIDINE | COPPER(II) | STATE | CHEMISTRY, MULTIDISCIPLINARY | HYDROGEN | O-2 | COUPLED ELECTRON-TRANSFER | METAL-COMPLEXES | Oxidation-reduction reaction | Ligands | Synthesis | Catalysts | Electrocatalysts | Joining | Oxidation | Catalysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 338 - 351
The addition of abiraterone and prednisolone to standard androgen-deprivation therapy as the first treatment for patients with locally advanced or metastatic...
ZOLEDRONIC ACID | SURVIVAL | MEDICINE, GENERAL & INTERNAL | PLUS PREDNISONE | CONTROL ARM | STAMPEDE TRIAL | OPEN-LABEL | MULTISTAGE | RANDOMIZED CONTROLLED-TRIAL | DOCETAXEL | MULTIARM | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Care and treatment | Prostate cancer | Prednisolone | Medical research | Prostate-specific antigen | Clinical trials | Endocrine therapy | Oncology | Metastasis | Radiation therapy | Cancer therapies | Metastases | Mens health | Androgens | Medical prognosis | Death | Prostate
ZOLEDRONIC ACID | SURVIVAL | MEDICINE, GENERAL & INTERNAL | PLUS PREDNISONE | CONTROL ARM | STAMPEDE TRIAL | OPEN-LABEL | MULTISTAGE | RANDOMIZED CONTROLLED-TRIAL | DOCETAXEL | MULTIARM | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Care and treatment | Prostate cancer | Prednisolone | Medical research | Prostate-specific antigen | Clinical trials | Endocrine therapy | Oncology | Metastasis | Radiation therapy | Cancer therapies | Metastases | Mens health | Androgens | Medical prognosis | Death | Prostate
Journal Article